VivoSeq
Infectious Disease

Dengue Hemorrhagic Fever

4

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

Dengue Hemorrhagic Fever is an early-stage landscape with 4 programs across 3 companies. The most active players are Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Milestone Pharmaceuticals Inc., Sanofi. 3 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

N/A

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

ApprovedM

Milestone Pharmaceuticals Inc.

1 program

ApprovedSanofi logo

Sanofi

1 program

Approved

Pipeline

Programs by Phase

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)